I'm pretty sure, considering all the patients in this trial are refractory to the first and second line settings, makes P a "lock" in all refractory patients...not just T315i patients.
The FDA would have to be serious crooks to not approve P based on ANY of the data that we have seen to date.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.